Effects of Lonidamine on pituitary-gonadal axis in man.
Lonidamine was given for 3 weeks at the dose of 150 mg three times daily to 6 male cancer patients. Serum follicle-stimulating and luteinizing hormone levels were significantly higher as compared to pretreatment values after 1 and 3 weeks of Lonidamine administration, while testosterone, prolactin, and thyroid-stimulating hormone levels remained unchanged.
D000368:Aged; D000988:Antispermatogenic Agents / Q000494:pharmacology*; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007191:Indazoles / Q000494:pharmacology*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D010902:Pituitary Gland / Q000187:drug effects / Q000502:physiology*; D011388:Prolactin / Q000097:blood; D011720:Pyrazoles / Q000494:pharmacology*; D013737:Testis / Q000187:drug effects / Q000502:physiology*; D013963:Thyroid Hormones / Q000097:blood; D013997:Time Factors
D000988:Antispermatogenic Agents; D007191:Indazoles; D011720:Pyrazoles; D013963:Thyroid Hormones; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; C016371:lonidamine